Median survival extended by 5.7 months! Roche's (RHHBY.US) new lung cancer drug wins in a head-to-head trial, a major catalyst for its oncology business

Zhitong Finance APP has learned that Swiss healthcare and pharmaceutical supergiant Roche's investigational lung cancer drug divarasib, in a late-stage clinical trial, extended median survival by nearly six months compared with competing therapies, and is expected to further strengthen the Swiss pharmaceutical company's oncology treatment portfolio.